DRD2 and schizophrenia: The more recent introduction of aripiprazole seemed to provide a different approach to schizophrenia treatment; acting largely on the dopamine D2 receptor (similar to first generation typical antipsychotic drugs) but with a lower risk of inducing EPS, it could treat broader symptoms of schizophrenia (similar to some second generation atypical antipsychotics) but had a lower metabolic liability (50).